BETHESDA, Md-The new year will bring a new and controversial source for obtaining access to new scientific studies in the life sciences. In January, the National Institutes of Health (NIH) will launch PubMed Central, a free on-line repository of research reports, found at http://www.ncbi.nlm.nih.gov/PubMed/.
BETHESDA, MdThe new year will bring a new and controversial source for obtaining access to new scientific studies in the life sciences. In January, the National Institutes of Health (NIH) will launch PubMed Central, a free on-line repository of research reports, found at http://www.ncbi.nlm.nih.gov/pubmed/.
The site will store, organize, and distribute articles, preprints, and screened reports contributed to the repository by scientific journals and reputable scientific organizations. It is unclear, however, to what extent peer-reviewed journals will cooperate with the new venture.
PubMed Central is an expanded form of E-biomed, which NIH director Harold E. Varmus, MD, originally proposed in May as a cyberspace library for the biomedical sciences. His idea drew considerable criticism from companies and organizations that publish scientific journals, which feared the free service would cost them subscribers. The plan was also criticized for the use of materials that were not peer reviewed.
Efficacy and Safety of Zolbetuximab in Gastric Cancer
Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.
These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.